N. Lokker

发表

Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.

M. Israel, N. Giese, N. Lokker, 2002, Cancer research.

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.

D. Gilliland, J. Cools, D. Curley, 2004, Blood.

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

Donna Neuberg, Keith Abe, Ifor Williams, 2002, Cancer cell.

Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury.

K. Matsuno, A. Betz, Jin-Chen Yu, 2001, The Journal of pharmacology and experimental therapeutics.

May Play a Role in the Development of Brain Tumors Cells : Evidence That the Novel PDGF-C and PDGF-D Ligands Regulates Survival and Mitogenic Pathways in Glioblastoma Platelet-derived Growth Factor ( PDGF ) Autocrine Signaling

M. Israel, N. Giese, N. Lokker, 2002 .

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.

W. Gradishar, D. Lokanatha, V. Raina, 2013, European journal of cancer.

Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1.

P. Godowski, N. Lokker, 1993, The Journal of biological chemistry.

RP-1551s, a family of azaphilones produced by Penicillium sp., inhibit the binding of PDGF to the extracellular domain of its receptor.

Y. Matsuda, T. Tanaka, N. Giese, 1999, The Journal of antibiotics.

RP-1776, a novel cyclic peptide produced by Streptomyces sp., inhibits the binding of PDGF to the extracellular domain of its receptor.

K. Ochiai, S. Nakanishi, Y. Matsuda, 2001, The Journal of antibiotics.

Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives.

K. Matsuno, Jin-Chen Yu, N. Giese, 2002, Journal of medicinal chemistry.

Structure‐activity relationship study of human interleukin‐3: role of the C‐terminal region for biological activity.

B. Fagg, N. Movva, N. Lokker, 1991, The EMBO journal.

Structure-Function Analysis of Hepatocyte Growth Factor and its Tyrosine-Kinase Receptor c-Met

P. Godowski, M. Mark, N. Lokker, 1993 .

Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding.

P. Godowski, M. Mark, N. Lokker, 1992, The Journal of biological chemistry.

P1.01A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)

W. Eiermann, H. Rugo, M. Martín, 2015 .

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

C. Hudis, H. Rugo, C. Isaacs, 2013, Clinical Cancer Research.

Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations

S. Bohlander, D. Tenen, Tajhal Dayaram, 2006, The Journal of experimental medicine.

PDGF-D, a new protease-activated growth factor

J. Rothberg, Meijia Yang, R. Shimkets, 2001, Nature Cell Biology.

Structure‐function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding.

P. Godowski, M. Mark, J. Baker, 1992, The EMBO journal.

A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).

P. Fasching, M. Robson, A. Wardley, 2015 .

A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).

W. Eiermann, H. Rugo, Y. Im, 2015 .

Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer

E. Jaffee, L. Coussens, elliot k fishman, 2019, Clinical Cancer Research.

Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer

W. Eiermann, Y. Im, M. Martín, 2016 .

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

R. Salazar, E. Van Cutsem, J. Tabernero, 2013, Clinical Cancer Research.

Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution.

M. Ultsch, A. D. de Vos, P. Godowski, 1998, Structure.

Crystal structure of the NK 1 fragment of human hepatocyte growth factor at 2 . 0 Å resolution

M. Ultsch, P. Godowski, A. D. Vos, 1998 .

Functional Importance of Platelet-derived Growth Factor (PDGF) Receptor Extracellular Immunoglobulin-like Domains

V. Ramakrishnan, L. Fretto, J. Tomlinson, 1997, The Journal of Biological Chemistry.

PDGF C Is A Selective &agr; Platelet-Derived Growth Factor Receptor Agonist That Is Highly Expressed in Platelet &agr; Granules and Vascular Smooth Muscle

P. Nurden, L. Komuves, B. Stringer, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Purification and characterization of natural human interleukin-3.

S. Geisse, B. Fagg, N. Lokker, 1991, Lymphokine and cytokine research.

Mapping the epitopes of neutralizing anti-human IL-3 monoclonal antibodies. Implications for structure-activity relationship.

B. Fagg, N. Lokker, H. Kocher, 1991, Journal of immunology.

Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor.

L. Presta, P. Godowski, N. Lokker, 1994, Protein engineering.

Structure-activity relationship study of human interleukin-3. Identification of residues required for biological activity by site-directed mutagenesis.

B. Fagg, N. Movva, N. Lokker, 1991, The Journal of biological chemistry.

Expression and Characterization of Hepatocyte Growth Factor Receptor-IgG Fusion Proteins

P. Godowski, M. Mark, N. Lokker, 2022 .